Oncology
Publications
The content contained herein is for educational purposes only. No reproduction, alteration, or distribution of this information is permitted. Relacorilant (LIFYORLI™) is U.S. FDA approved for use in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab. All other indications are under investigation, and the safety and efficacy of such investigational uses have not been established by the FDA, EMA, or any regulatory authority. There is no guarantee that these products will be approved for the indications under investigation
Access Corcept-sponsored oncology publications below.
Filter by:
2026
Relacorilant
Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer
Flint MS, O’Malley DM, Lorusso D, et al.
2026
Relacorilant
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
Lorusso D, Gladieff L, O’Malley DM, et al.
2025
Relacorilant
Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)
Shahin MS, Mathur R, Parthan A, et al.
2025
Relacorilant
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
Olawaiye AB, Gladieff L, O'Malley DM, et al.
2023
Relacorilant
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study
Colombo N, Van Gorp T, Matulonis UA, et al.
2023
Relacorilant
The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol
Greenstein AE, Hunt HJ
2023
Relacorilant
Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators
Mallick S, Chakrabarti J, Eschbacher J, et al.
2022
Relacorilant
Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant
Pivonello R, Munster PN, Terzolo M, et al.
2022
Relacorilant
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Munster PN, Greenstein AE, Fleming GF, et al.
2021
Relacorilant
Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells
Greenstein AE, Hunt HJ
2021
Relacorilant
Adrenal tumors provide insight into the role of cortisol in NK cell activity
Greenstein AE, Habra MA, Wadekar SA, et al.
2017
Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth
Kach J, Long TM, Tonsing-Carter EY, et al.
2017
Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay
Block TS, Murphy TI, Munster PN, et al.
2017
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer
Veneris JT, Darcy KM, Mhawech-Fauceglia P, et al.
2016
Mifepristone
A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer
Nanda R, Stringer-Reasor EM, Saha P, et al.
2015
Relacorilant
Mifepristone
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma
Stringer-Reasor EM, Baker GM, Skor MN, et al.
2015
Mifepristone
Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer
Baker GM, Murphy TI, Block TS, et al.
2014
Mifepristone
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer
Isikbay M, Otto K, Kregel S, et al.
2014
Steroid receptors aplenty in prostate cancer
Sharifi N
2013
Mifepristone
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer
Skor MN, Wonder EL, Kocherginsky M, et al.
2012
Mifepristone
Mifepristone inhibits GRβ coupled prostate cancer proliferation
Ligr M, Li Y, Logan SK, et al.
2011
“Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers
Nanda R
2011
Mifepristone
Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression
Tiezen CR, Goyeneche AA, Brandhagen BN, et al.
2009
Administration of Glucocorticoids to Ovarian Cancer Patients Is Associated with Expression of the Anti-apoptotic Genes SGK1 and MKP1/DUSP1 in Ovarian Tissues
Melhem A, Yamada SD, Fleming GF, et al.
2008
Minireview: nuclear receptors and breast cancer
Conzen SD
2008
Mifepristone
Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer
Yan TZ, Jin FS, Xie LP, et al.
2008
Mifepristone
Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro
Zhang H, Lü J, Gao Q, et al.
1999
The biology of hormone refractory prostate cancer. Why does it develop?
Isaacs JT.